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Who Are Less Likely to Receive Subsequent Chemotherapy
Beyond First-Line Therapy for Advanced Non-small Cell
Lung Cancer?
Implications for Selection of Patients for Maintenance Therapy
Jong-Mu Sun, MD, Joon Oh Park, MD, PhD, Young-Woong Won, MD, Jung-Hoon Kim, MD,
Jina Yun, MD, Jeeyun Lee, MD, Yeon Hee Park, MD, PhD, Jin Seok Ahn, MD, PhD,
Myung-Ju Ahn, MD, PhD, and Keunchil Park, MD, PhD
Background: Prospective studies have implied that maintenance
therapy for non-small cell lung cancer (NSCLC) has its effect by
giving active drugs earlier to patients who otherwise die without
receiving second-line therapy. The purpose of this study was to
select patients with NSCLC who could most benefit from mainte-
nance therapy, by evaluating which patients would be less likely to
receive second-line therapy.
Methods: Clinicopathologic data of patients with advanced NSCLC
who received four cycles of first-line chemotherapy followed by
time-off therapy and eventual disease progression or death were
reviewed retrospectively. Patients were grouped into ones with
first-line therapy only or ones with more than first-line therapy.
Clinical characteristics between the two groups were compared.
Results: A total of 271 patients were eligible for analysis, and 39
patients (14.4%) received only first-line therapy. Patients signifi-
cantly more likely to receive only first-line therapy had performance
status of two or three after first-line therapy, large volume of initial
target lesions (sum of long diameters 70 mm), or smaller decrease
in target lesions (decrease 20%) after first-line therapy. Median
overall survival of the 143 patients (52.8%) with at least one of these
characteristics (16.3 months) was significantly shorter than that of
patients without any of these characteristics (23.5 months, p 
0.007).
Conclusion: Maintenance therapy may be of greater benefit to
patients with NSCLC who have clinical characteristics including
poor performance status after first-line therapy, large initial target
lesions, or smaller decrease in target lesions after first-line
therapy.
Key Words: Maintenance therapy, Non-small cell lung cancer,
Patient selection, Survival, Quality of life.
(J Thorac Oncol. 2010;5: 540–545)
The current practice of first-line therapy for advanced non-small cell lung cancer (NSCLC) is four or six cycles of
platinum-based combination chemotherapy followed by treat-
ment break in nonprogressive status, which prolongs overall
survival.1 Despite modest progress in improving overall sur-
vival, the majority of patients experience disease progression
and need further systemic treatment. One strategy to improve
survival has been to use maintenance therapy in patients who
derive benefit from first-line therapy.2–5 Although the definition
of maintenance therapy is controversial, it can be recognized as
two designs. The first design is the continuation of the same drug
used in initial therapy until a specified number of extended
cycles or disease progression. The other design is switching to a
different drug before disease progression after a defined number
of cycles of first-line therapy.
In an era when many drugs approved for second-line
therapy are available, the early switching to a noncross resistant
second-line drug seems reasonable, and its efficacy has been
demonstrated recently. In two recent trials, immediate switching
to docetaxel or pemetrexed after four cycles of first-line therapy
improved progression-free survival and overall survival signifi-
cantly, when compared with delayed administration of second-
line drugs at the time of disease progression.6,7 However, one
reason for lower survival with delayed therapymay be that many
patients randomly assigned to the delayed arm never receive
further systemic therapy: 37 and 33% of patients in the delayed
arm did not receive second-line therapy in the studies with
docetaxel and pemetrexed, respectively. Overall survival for
patients who actually received docetaxel at the time of progres-
sion in the delayed arm was identical to that of patients with
immediate docetaxel therapy.
These findings imply that the efficacy of maintenance
therapy may be greater for patients who would have no
chance to receive active second-line drugs if they had not
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received it immediately after first-line therapy. Thus, the
selection of patients less likely to receive second-line therapy
later is important at the time of deciding whether to maintain
or delay therapy after four or six cycles of platinum-based
first-line therapy. Maintenance therapy for selected patients
rather than all patients will decrease the cost and inconve-
nience of maintenance therapy without impairing its efficacy.
The aim of our study was to select patients who could
most benefit from maintenance therapy, by identifying pa-
tients more likely to be unable to receive second-line therapy
after being off therapy with nonprogressive disease after four
cycles of first-line therapy for advanced NSCLC.
PATIENTS AND METHODS
We retrospectively screened consecutive patients who
received first-line chemotherapy for advanced NSCLC at
Samsung Medical Center between January 2003 and Decem-
ber 2008. The study population comprised patients who were
off therapy with nonprogressive disease and did not receive
maintenance therapy after four cycles of platinum-based
first-line therapy. The decision to discontinue chemotherapy
after four cycles of first-line therapy was made at the clini-
cian’s discretion after discussion with the patient. During the
period of treatment break, the patients were followed up
monthly and were evaluated by computed tomography scan
every 3 months or when clinically indicated. Patients who
experienced disease progression or death while off therapy
were included in the analysis.
Clinicopathologic and follow-up data for these patients
up to August 2009 were retrieved from medical records.
Tumor burden was assessed by checking the number of
organs involved with lung cancer and by calculating the sum
of long diameters of target lesions based on the Response
Evaluation Criteria in Solid Tumor, version 1.0. We blindly
and independently evaluated change in target lesions by
reviewing radiologically the computed tomographic images
before and after two and four cycles of chemotherapy. This
study was approved by the Institutional Review Board of
Samsung Medical Center.
Statistical Analysis
Statistical analysis compared overall survival between
patients who received first-line therapy only and patients who
had more than first-line therapy by using the log-rank test.
Overall survival encompassed the time from the first cycle of
first-line therapy until the date of death or the last docu-
mented follow-up.
Clinical characteristics including sex, age, smoking
status, performance status at the time of decision to discon-
tinue chemotherapy, histology, stage, history of brain metas-
tasis, the number of organs involved with lung cancer, regi-
men of first-line therapy, the sum of long diameters of all
target lesions before and after first-line therapy, and the
amount of decrease of target lesions during first-line therapy
were evaluated as possible predictive indicators of the like-
lihood of receiving second-line therapy. The proportions of
these characteristics between groups with first-line therapy
only and with more than first-line therapy were compared
using univariate analysis and multivariate logistic regression
analysis. To evaluate more exactly the relationship between
response to first-line therapy and the likelihood of receiving
second-line therapy, we compared the proportion of patients
whose target lesions decreased by 20 versus 20% in each
group and 30% (partial response) versus 30% (stable
disease). Tests were two sided, and p  0.05 was considered
statistically significant.
RESULTS
In total, 765 consecutive patients with advanced
NSCLC received first-line chemotherapy, including 271 pa-
tients (35.4%) who were off therapy with nonprogressive
disease after four cycles of first-line therapy but eventually
experienced disease progression or death, who formed the
study group for analysis. Patients excluded from analysis
included 297 patients (38.8%) who experienced disease pro-
gression or were lost to follow-up during four cycles of
first-line therapy, 145 patients (19.0%) who received more
than four cycles of first-line therapy, and 52 patients (6.8%)
who received maintenance therapy or had sustained nonpro-
gressive disease after first-line therapy.
Table 1 shows clinical characteristics for the total sample
and the subgroups who received first-line therapy only and who
received more than first-line therapy. Median follow-up was
14.3 months (95% confidence interval [CI]: 13.0–15.6 months).
Median age was 59 years (range, 23–77 years). Median interval
from decision to discontinue first-line therapy to first follow-up
was 28.0 days (95% CI: 26.9–29.1 days). Among 23 patients
with performance status of two or three at the time of decision
to discontinue first-line therapy, 19 patients (82.6%) had a good
performance status (0 or 1) before first-line chemotherapy. Of
the 271 patients in the study sample, 253 patients (93.4%) had at
least one target lesion.
Among the 271 patients, 39 patients (14.4%) could not
receive second-line therapy after four cycles of first-line
chemotherapy because of disease progression and poor per-
formance status (n  31), death (n  4), and patients’ refusal
(n  4). For the 232 patients (85.6%) who received second-
line therapy at the time of disease progression, the regimens
were pemetrexed (n 71), docetaxel (n 48), gefitinib (n
46), gemcitabine (n 32), erlotinib (n 29), and others (n
6). Median interval from the date of decision to discontinue
first-line therapy to the date of disease progression was
significantly shorter in the group who received first-line
therapy only (1.9 months) than in the group with more than
first-line therapy (3.2 months, p  0.001). In addition, me-
dian survival of patients who received first-line therapy only
(6.7 months) was significantly shorter than that of patients
who received more than first-line therapy (23.0 months, p 
0.001, Figure 1).
Clinical characteristics were compared between groups
with first-line therapy only and with more than first-line
therapy (Table 1). Significantly, more patients with poor
performance status after chemotherapy, large volume of tar-
get lesions before and after first-line therapy, and with less
decrease in target lesion size during first-line therapy could
not receive second-line therapy in univariate analysis. Me-
dian interval from decision to discontinue first-line therapy to
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first follow-up was not different between the two groups (28
days versus 30 days, p  0.38).
In multivariate analysis, clinical characteristics includ-
ing poor performance status, large volume of target lesions
before therapy, and less decrease of target lesions during
first-line therapy were significantly associated with a greater
likelihood of receiving only first-line therapy (Table 2).
Among the study population, 143 patients (52.8%) had at
least one of these clinical characteristics, and their median
overall survival was significantly shorter (16.3 months) than
TABLE 1. Comparison of Clinical Characteristics Between Groups with First-Line
Therapy Only and with More Than First-Line Therapy
Characteristics
All Patients,
n (%)
Patients with
First-Line Therapy
Only, n (%)
Patients with
More Than First-Line
Therapy, n (%) p
All patients (%) 271 (100) 39 (100) 232 (100)
Sex
Male 189 (69.7) 32 (82.1) 157 (67.7) 0.07
Female 82 (30.3) 7 (17.9) 75 (32.3)
Elderly
Age 65 yr 84 (31.0) 16 (41.0) 68 (29.3) 0.14
Age 65 yr 187 (69.0) 23 (59.0) 164 (70.7)
Performance status after
first-line therapy
0 or 1 248 (91.5) 30 (76.9) 218 (94.0) 0.001
2 or 3 23 (8.5) 9 (23.1) 14 (6.0)
Smoking
Ever 167 (61.6) 29 (74.4) 138 (59.5) 0.08
Never 104 (38.4) 10 (25.6) 94 (40.5)
Histology
Adenocarcinoma 187 (69.0) 29 (74.4) 158 (68.1) 0.43
Nonadenocarcinoma 84 (31.0) 10 (25.6) 74 (31.9)
Stage
IIIB 56 (20.7) 6 (15.4) 50 (21.6) 0.38
IV 215 (79.3) 33 (84.6) 182 (78.4)
Brain metastasis before therapy
Yes 40 (14.8) 8 (20.5) 32 (13.8) 0.27
No 231 (85.2) 31 (79.5) 200 (86.2)
Number of involved organs
3 38 (14.0) 5 (12.8) 33 (14.2) 0.82
3 233 (86.0) 34 (87.2) 199 (85.8)
Regimen of first-line therapy
Gemcitabine plus platinum 202 (74.5) 29 (74.4) 173 (74.6) 0.97
Paclitaxel plus platinum 16 (5.9) 2 (5.1) 14 (6.0)
Docetaxel plus platinum 52 (19.2) 8 (20.5) 44 (19.0)
Etoposide plus platinum 1 (0.4) 0 (0) 1 (0.4)
Sum of long axes of target lesions
before therapy
253 (100) 37 (100) 216 (100) 0.03
70 mm 49 (19.4) 12 (32.4) 37 (17.1)
70 mm 204 (80.6) 25 (67.6) 179 (82.9)
Sum of long axes of target lesions
after therapy
253 (100) 37 (100) 216 (100) 0.036
50 mm 50 (19.8) 12 (32.4) 38 (17.6)
50 mm 203 (80.2) 25 (67.6) 178 (82.4)
Decrease in target lesion 253 (100) 37 (100) 216 (100) 0.12
30%a 141 (55.7) 25 (67.6) 116 (53.7)
30%a 112 (44.3) 12 (32.4) 100 (46.3)
Decrease in target lesion 253 (100) 37 (100) 216 (100) 0.015
20% 98 (38.7) 21 (56.8) 77 (35.6)
20% 155 (61.3) 16 (43.2) 139 (64.4)
a The amount of the change represented stable disease (decrease 30%) and partial response (decrease 30%) by response
evaluation criteria in solid tumor.
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that of patients without any of these characteristics (23.5
months, p  0.007, Figure 2).
DISCUSSION
The optimal therapeutic approach for advanced NSCLC
has been increasingly difficult to define. First-line therapy for
advanced NSCLC is commonly done with four cycles (in
some cases with six cycles) of platinum-based doublets.8
However, there is no consensus regarding the appropriate
treatment strategy for patients who are in nonprogressive
status after the completion of platinum-based first-line ther-
apy. Many patients have a treatment break, and second-line
therapy is administered at the time of disease progression.
The value of delayed administration of second-line therapy
was recently supported by the observation of Fidias et al.7
that overall survival for patients on the delayed docetaxel arm
who actually received docetaxel was identical with that of
patients on immediate docetaxel arm. However, many pa-
tients never receive second-line therapy due to rapid disease
progression combined with deteriorating performance status
after a certain period of treatment break, and they die earlier.
Maintenance therapy is used to address this shortcoming of
current practice.
The extended administration of effective first-line ther-
apy has been tried in many studies.9–14 First-line chemother-
apy was administered until a defined number of extended
cycles or disease progression. In a previously reported
study,14 we randomly assigned patients without progression
after two cycles of a platinum doublet to either two or four
more chemotherapy cycles of the same. There was no differ-
ence in the primary end point, 1-year survival, despite of time
to progression favoring the more chemotherapy arm (6.2
versus 4.6 months, p  0.001). More patients who received
less first-line therapy were able to eventually receive more
second-line therapy (74.4 versus 62.7%, p  0.026), perhaps
accounting for the lack of difference in overall survival
between the two arms. Many studies also failed to demon-
strate improved survival with extended first-line therapy. In
addition, toxicity was greater, and quality of life was worse
with prolonged initial therapy in meta-analysis. Thus, the
prevailing opinion was that a brief duration of initial first-line
therapy is best. However, a recently published phase II study
showed that pemetrexed and carboplatin plus bevacizumab
with maintenance pemetrexed and bevacizumab as first-line
therapy for nonsquamous NSCLC provided progression-free
survival of 7.8 months and overall survival of 14.1 months.15
In view of the modest toxicity of pemetrexed, maintenance
pemetrexed therapy after initial therapy with pemetrexed plus
platinum could be a promising treatment sequence, and we
anticipate the results of an ongoing phase III trial.16
FIGURE 1. Overall survival curves of patients who received
first-line therapy only and patients who received more than
first-line therapy.
TABLE 2. Multivariate Analysis of Clinical Characteristics
Associated with Receiving Only First-Line Therapy
Characteristics Odds Ratio 95% CI
Poor performance status after first-line
therapy: 2 or 3 (vs. 0 or 1)
4.83 1.75–13.36
Less decrease in target lesions after
first-line therapy: 20% (vs. 20%)
2.47 1.12–5.44
Great sum of long axes of target lesions
before first-line: therapy 70 mm
(vs. 70 mm)
3.83 1.02–14.36
Great sum of long axes of target lesions
after first-line therapy: 50 mm
(vs. 50 mm)
0.72 0.20–2.61
CI, confidence interval.
FIGURE 2. Overall survival curves of patients with and
without the clinical characteristics including poor perfor-
mance status at the time of decision to discontinue first-line
therapy, large target lesions before first-line therapy, or less
decrease in target lesions after first-line therapy.
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On the other hand, maintenance therapy with an alter-
native effective drug after initial chemotherapy has already
validated its role by showing significantly increased overall
survival. In the clinical trial in advanced NSCLC reported by
Ciuleanu et al.,6 patients received platinum-based doublet
regimen as first-line therapy. Those without progression after
four cycles of chemotherapy were randomly assigned to
pemetrexed or placebo. Median overall survival was 10.6
months in the placebo group compared with 13.4 months in the
pemetrexed group (95% CI: 0.65–0.91). In another study, se-
quential erlotinib immediately after four cycles of platinum-
based doublet extended overall survival compared with the
control arm (95% CI: 0.70–0.95).17 However, a considerable
number of patients in the control arm could not receive effective
second-line drugs when disease progression was detected.6,7,17
These findings suggest that improved survival with maintenance
therapy can be attributed to the fact that more patients are able
to receive more active drugs. Thus, maintenance therapy may
achieve its effect because active drugs administered before
disease progression can prevent complications of the disease
from rendering patients unable to receive it. On the basis of this
reasoning and the fact that the cost and inconvenience of main-
tenance therapy is substantial, we tried to select patients who
could most benefit frommaintenance therapy after four cycles of
first-line therapy.
This retrospective analysis showed that patients with
poor performance status at the time of decision to discontinue
first-line therapy, large volume of target lesions before first-
line therapy, or less decrease in target lesions after first-line
therapy were more likely to receive only first-line therapy
(i.e., to be unable to receive second-line therapy). Thus, we
suggest that earlier or immediate administration of effective
drugs should be considered to these patients after first-line
therapy.
Significantly, more patients with poor performance sta-
tus at the time of discontinuing first-line chemotherapy did
not receive second-line therapy. Change in performance sta-
tus during first-line therapy may be associated with disease
progression or treatment. Most patients with poor perfor-
mance status after first-line therapy had good performance
status before platinum-based first-line chemotherapy. This
finding suggests that deteriorating performance status could
be caused in part by platinum-based chemotherapy, because
there was no definite disease progression during their first-
line therapy. Newly proven second-line drugs, such as pem-
etrexed or erlotinib, have less toxicity than other chemother-
apeutic agents.18,19 Maintenance therapy with more tolerable
second-line drugs for patients with deteriorating performance
status after initial platinum-based chemotherapy may be a
useful strategy to improve survival without further undermin-
ing performance status.
Tumor burden assessed by the number of cancer-in-
volved organs was not associated with the probability of
receiving second-line therapy. We also evaluated whether the
metastatic site would impact the probability of receiving
second-line therapy. There was a trend for patients with brain
metastasis to be less likely to receive second-line therapy but
without statistical significance (p  0.27). Other metastatic
sites, such as liver and bone, also did not impact on whether
patients received second-line therapy.
Another strategy to improve treatment outcome might
be the early detection of disease progression using careful
follow-up after the completion of first-line therapy. The
interval of follow-up should be individualized depending on
the clinical presentation and pace of disease progression. Our
results showed that disease progressed more rapidly in pa-
tients who could not receive second-line therapy after dis-
continuing first-line therapy. Based on our results, patients
with characteristics including poor performance status, large
volume of initial target lesions, and less decrease in target
lesions should be followed up more closely if they do not
receive maintenance therapy.
Our study had some limitations. It was retrospective in
nature, and the study population was too small to conclude
which patients should or should not receive maintenance
therapy. Furthermore, this study is based on a basic premise
but unvalidated that maintenance therapy may be most ben-
eficial for patients who would have no chance to receive
active second-line drugs if they had not received it immedi-
ately after first-line therapy. Therefore, it is too premature to
be applied directly to the clinical practice, and we need
additional studies for confirmation. In addition, the propor-
tion of patients who did not receive second-line therapy
(14.4%) was much lower than that of prospective studies (37
or 33%). This phenomenon can be explained by the relatively
frequent follow-up after completion of first-line therapy in
our patient population. Despite these limitations, to our
knowledge, this study is the first attempt to select patients for
maintenance therapy in NSCLC.
In summary, maintenance therapy before disease pro-
gression would benefit some patients with NSCLC in terms of
survival. However, the important goal of cancer treatment is
decreasing treatment-associated toxicity and extending sur-
vival. Therefore, maintenance therapy should be reserved for
selected patients who will most benefit from it. Clinical
characteristics including poor performance status after first-
line therapy, large volume of target lesions before first-line
therapy, and less decrease in target lesions after first-line
therapy were associated with a lower likelihood of receiving
subsequent lines of therapy beyond first-line therapy, and
patients with these characteristics may benefit the most from
maintenance therapy.
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